Epithelial dysplasia of gall bladder is an important precancerous lesion of gall bladder carcinogenesis. To investigate the frequency of K-ras gene mutation in gall bladder carcinoma and dysplasia, K-ras codon 12 mutations were investigated by the polymerase chain reaction/restriction enzyme based method foliowing direct sequencing. Mutation was detected in 59%/o (30 of 51) of gall bladder carcinomas, in 730/0 (8 of 11) of gall bladder dysplasia in gall stone cases, and in 00/0 of the normal gall bladder epithelium. There was, however, no correlation between K-ras mutation and clinicopathological factors of gall bladder carcinoma. K-ras gene mutation occurs even in gall bladder dysplasia at an incidence similar to that in carcinomas, suggesting that testing for K-ras gene mutation may prove useful as an adjunct to bile cytological or biopsy analysis. (Gut 1996; 38: 426-429) 
Previous investigations have show that K-ras activation may be important in the neoplastic process.1 The development of pancreatic and colonic cancer is associated with a high frequency of K-ras oncogene activation, which has been recognised as an early event in their carcinogenesis.2 3 In contrast, several reports have stated that K-ras mutation is a later occurrence during tumour progression of myeloid leukaemia4 and pancreatic cancer.5 Furthermore, at least some ras mutations have been reported to occur at various points during the evolution of tumours. 4 6 In biliary tract carcinomas, a low frequency of K-ras mutations had been noted; recently, however, by using a sensitive detection method a higher frequency has been reported.6-8 These differences seem to result from the varying sensitivities of the methods used in the detection of such mutations.
Adenoma9 and epithelial dysplasia'0 have been recognised as precancerous lesions in the gall bladder tumour. Two studies have reported the occurrence of K-ras codon 12 mutation in gall bladder adenoma, supporting the adenoma-carcinoma theory of gall bladder carcinoma. 6 7 While adenoma of the gall bladder is very rare and dysplasia is believed to be a significant precancerous lesion for gall bladder carcinomas, there is no report dealing with K-ras mutation of this lesion.
In this study, we have examined K-ras mutation in gall bladder carcinoma and dysplasia by using the highly sensitive polymerase chain reaction (PCR)/restriction enzyme based method, and have also investigated the relation between K-ras mutation and clincopathological factors to elucidate the significance of K-ras mutation in the evolution of gall bladder tumours.
Methods
Fifty one gall bladder carcinomas, 11 (Fig 1) , as reported by Dowling et al. 10 The SW480 cultured colon carcinoma cell line that contains K-ras mutation at codon 12 was 
The underlined base represents a mismatch from the K-ras DNA sequence, which produces an Mva I (Takara, Shuzo, Kyoto, Japan) recognition site when codon 12 is normal. Primers were synthesised using a DNA synthesiser (Applied Biosystems, model 380A, Tokyo, Japan). The first PCR with primers A and B gave rise to a 157 base pair (bp) fragment containing Mva I restriction sites when codon 12 was normal. Twenty jil of the product was digested with 10 units of Mva I and electrophoresed on a 3% agarose gel. Digested DNA was diluted with H20 (1:100), and one jil of the sample was amplified in the second PCR with primers A and C, generating a 129 bp fragment also containing Mva I restriction site when codon 12 was normal. Twenty jil ofthe second PCR product was also digested with 10 units of Mva I and electrophoresed on a 3% agarose gel. The mutation bands detected by the above assay were purified using EASYTRAP (Takara, Kyoto, Japan) and confirmed by direct sequencing done by the dideoxy procedure using the DNA Sequencing System (Promega, Madison, WI, USA). In accordance with the manufacturer's instructions, 10 ng of the template DNA were mixed with 3 pmol of the C primer, 5 Figure 2 shows representative analysis of the two step PCR/restriction enzyme based method for K-ras codon 12. Table I summarises the frequency ofK-ras mutation as codon 12 in biliary tract tumours. The positive rate in gall bladder dysplasia or intrahepatic bile duct carcinoma was higher than that in extrahepatic bile duct carcinoma or gall bladder carcinoma, but these did not reach statistical differentiation. No mutation was detected in normal gall bladder epithelium.
Nine cases in our study exhibited dysplastic lesion in the area surrounding the carcinoma. These cases displayed the same K-ras mutation both in dysplastic and in carcinomatous lesions. Table II summarises K-ras mutations and histopathological factors in gall bladder tumours. The frequency of K-ras mutations in gall bladder carcinomas in situ (Tis) was lower than those in epithelial dysplasia and in advanced gall bladder carcinomas, but did not reach statistical significance. There was no correlation between K-ras mutation and the distribution of dysplasia or histological subtype. The frequency of K-ras mutation in gall bladder carcinoma patients with stones was relatively higher than that in those without stones (p=0 157). K-ras mutation in dysplasia in gall stone cases was a G to T transversion (GGT-*GT-T) in four cases and a G to A transition (GGT--ACT) in four cases (Fig 3) .
Discussion
Our results have confirmed that ras activation is already associated with the preinvasive event creatic or colonic carcinomas.'9 Secondly, the chronic inflammatory change caused by stone retention or longtime bile exposure may correlate with the ras gene change. In fact, it is generally accepted that physical stimulation by stones is related to carcinogenesis in the gall bladder.20 In our study K-ras mutation was more frequently detected in gall bladder carcinomas with stones than in those without stones. Further, as bile salts act as a detergent in removing components from the plasma membrane,21 and as the bile components in carcinoma cases are different from benign cases,22 there may be a continuous initiation of K-ras activation in carcinoma cases.
The two step PCR method is non-radioactive and highly sensitive in detecting a small population of mutated alleles,23 and its sensitivity is reported to be one in 512.8 The possibility of a sequencing error due to the Taq polymerase base misincorporation, however, has to be ruled out. In our study, normal gall bladder epithelium was always used as a negative control and the mutations following the direct sequencing method were confirmed. Chen et al reported that the Taq polymerase induced mutations were multiple base transitions.24
In conclusion, we have shown that carcinomas and epithelial dysplasia of gall bladder contain K-ras gene mutation. Thus the detection of K-ras gene mutation may prove useful as an adjunct to bile cytological or biopsy analysis and make possible the selection of patients for surgical resection. Further investigation is indicated for other genetic abnormalities because carcinogenesis implies a number of genetic changes involving oncogenes and tumour suppressor genes.
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